Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin

被引：0
|
作者：
Elisabeth E. Fransen van de Putte
Laura S. Mertens
Richard P. Meijer
Michiel S. van der Heijden
Axel Bex
Henk G. van der Poel
J. Martijn Kerst
Andries M. Bergman
Simon Horenblas
Bas W. G. van Rhijn
机构：
[1] The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital,Department of Urology
[2] University Medical Center Utrecht,Department of Urology
[3] The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital,Department of Medical Oncology
来源：
World Journal of Urology | 2016年 / 34卷
关键词：
Bladder cancer; Neoadjuvant chemotherapy; Dose dense; MVAC; Cisplatin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：157 / 162
页数：5
相关论文
共 50 条
  • [31] An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer
    Montazeri, K.
    Dranitsaris, G.
    Thomas, JD.
    Curran, C.
    Preston, MA.
    Steele, GS.
    Kilbridge, KL.
    Mantia, C.
    Ravi, P.
    McGregor, BA.
    Mossanen, M.
    Sonpavde, G.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (12) : 834.e1 - 834.e7
  • [32] Neoadjuvant Gemcitabine Plus Cisplatin for Muscle-invasive Bladder Cancer
    Kaneko, Gou
    Kikuchi, Eiji
    Matsumoto, Kazuhiro
    Obata, Jun
    Nakamura, So
    Miyajima, Akira
    Oya, Mototsugu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (07) : 908 - 914
  • [33] Accelerated MVAC as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder
    Blick, C.
    Hall, P.
    Pwint, T.
    Munro, N.
    Crew, J.
    Powles, T.
    Macaulay, V. M.
    Al-Terkait, F.
    Protheroe, A.
    Chester, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [34] Neoadjuvant dose-dense gemcitabine and cisplatin (DDGC) in patients (pts) with muscle-invasive bladder cancer (MIBC): Final results of a multicenter phase 11 study.
    Plimack, Elizabeth R.
    Hoffman-Censits, Jean H.
    Kutikov, Alexander
    Greenberg, Richard E.
    Bilusic, Marijo
    Chen, David Y. T.
    Viterbo, Rosalia
    Lallas, Costas D.
    Lin, Jianqing
    Trabulsi, Edouard John
    Geynisman, Daniel M.
    Kelly, William Kevin
    Smaldone, Marc C.
    Devarajan, Karthik
    Adaire-Halenda, Beth
    Cione, Charlotte
    Kilpatrick, Deborah
    Duncan, Gail
    Wong, Yu-Ning
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] NEMIO: A randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) plus durvalumab plus /- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
    Thibault, C.
    Audenet, F.
    Borchiellini, D.
    Huillard, O.
    Barthelemy, P.
    Pouessel, D.
    Flechon, A.
    Blons, H.
    Sautes-Fridman, C.
    Sun, C-M.
    Verkarre, V.
    Pallet, N.
    Mejean, A.
    Rouabah, M.
    Helali, I.
    Elaidi, R-T.
    Oudard, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [36] Pathologic response rates between gemcitabine-cisplatin (GC) and methotrexate, vinblastine, doxorubicin hydrochloride, and cisplatin (MVAC) neoadjuvant chemotherapy in muscle-invasive urothelial cell carcinoma of the bladder
    Wright, Jonathan Lawrence
    Lee, Franklin
    Harris, William Proctor
    Cheng, Heather H.
    Zhao, Song
    Champion, Thomas
    Gore, John L.
    Dean, James
    Porter, Michael P.
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [37] Comparing clinical outcomes between patients with urothelial carcinoma who treated neoadjuvant chemotherapy by gemcitabine-cisplatin and dose dense MVAC.
    Lee, Yongjune
    Kim, Young Seok
    Hong, Bumsik
    Cho, Yong Mee
    Lee, Jae-Lyun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [38] Early outcomes with neoadjuvant high-dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (HD-MVAC) or gemcitabine and cisplatin (GC) in muscle-invasive urothelial carcinoma of the bladder: A single-institution experience
    Mitra, N.
    Monk, J. P., III
    Pohar, K. S.
    Shabsigh, A.
    Sharp, D. S.
    Abaza, R.
    Box, G. N.
    Zynger, D. L.
    Clinton, S. K.
    Mortazavi, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [39] Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer
    Narayan, Vivek
    Mamtani, Ronac
    Keefe, Stephen
    Guzzo, Thomas
    Malkowicz, S. Bruce
    Vaughn, David J.
    CANCER RESEARCH AND TREATMENT, 2016, 48 (03): : 1084 - 1091
  • [40] TOLERANCE AND OUTCOMES OF NEOADJUVANT DOSE-DENSE METHOTREXATE, VINBLASTINE, DOXORUBICIN, CISPLATIN FOR MUSCLE-INVASIVE BLADDER CANCER AT AN AUSTRALIAN TERTIARY REFERRAL CENTRE
    Mak, B.
    Sved, P.
    Vasilaras, A.
    Grimison, P.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 61 - 62
12345